Mitomycin C (MMC) was first discovered in the 1950s as an antibiotic and has since been used as a chemotherapeutic. MMC has been shown to cross-link DNA, resulting in cellular death. Synthetic aziridinomitosenes (AZMs) are structurally similar to MMC and have been shown to produce more DNA crosslinks than MMC, resulting in potential use as a new cancer treatment. Due to MMC's properties as a potent antibiotic, the synthetic AZMs also have possible use as antibiotics due to their similar structures. Growth inhibition assays of various gram positive and gram negative bacteria treated with MMC, an unsubstituted AZM, a C10-Methoxy AZM and a C6-Methyl AZM were evaluated. Initial results conclude that synthetic AZMs decrease bacterial growth with treatment as low as 1 nM in methicillin-resistant Staphylococcus aureus-1 (MRSA-1) by growth curves. Along with reduced survival rate, biofilm production was investigated, and shown to be affected upon AZM and MMC treatment.

Antibacterial properties of synthetic aziridinomitosenes

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.